Abstract: A cathode active material for a lithium secondary battery according to an embodiment includes a plurality of a lithium metal oxide particle that include a core containing a lithium iron phosphate-based compound and being doped with at least one metal element of Ti, V and Mn; and a carbon coating formed of the core. A ratio of an intensity of a peak corresponding to PO4 relative to an intensity of a D band measured by a Raman spectroscopy analysis is in a range from 0.10 to 0.33.

Abstract: Disclosed herein are a microorganism with excellent deacetoxycephalosporin C (DAOC) productivity and a use thereof. A mutant microorganism with improved DAOC productivity and a use thereof for producing 7-aminodeacetoxycephalosporanic acid (7-ADCA) are provided.

Abstract: The present invention provides a scalable digital twin system structure and a scalable digital twin service method that are capable of, based on a digital twin, performing real-time control of the real world while providing information required for the user to determine the optimal countermeasure in solve real-world problems in stages, thereby helping rapidly solve problems of the real-world. In order to preemptively respond to the real-world problems by providing decision support information with improved reliability according to a timeline based on a digital twin of a scalable structure, the operation of the digital twin is divided into several stages according to complexity and a result of each stage is transferred to an application service and the next stage, so that as the stage becomes higher, a more reliable result can be provided.

Abstract: Cathode active materials for lithium secondary batteries and lithium secondary batteries including the cathode active materials are disclosed. In some implementations, a cathode active material for a lithium secondary battery includes a lithium metal phosphate particle having a crystallite size in a range from 150 nm to 450 nm in a direction of a crystallographic plane (020) as measured by an X-ray diffraction (XRD) analysis. In some implementations, a lithium secondary battery includes a cathode including a cathode active material layer that includes a cathode active material for a lithium secondary battery, and an anode facing the cathode. In some implementations, an electrode crystallite size ratio defined by Equation 4 is in a range from 0.5 to 0.9.

Abstract: Disclosed is an ionomer for a high-temperature polymer electrolyte membrane fuel cell, which includes a phosphorus (P)-containing functional group having proton conductivity and partially contains fluorine in the main chain thereof.

Abstract: Provided are a compound capable of improving the light-emitting efficiency, stability, and lifespan of an element; an organic electronic element using same; and an electronic device thereof.

Abstract: A semiconductor memory device comprises a substrate including a first source/drain region and a second source/drain region, a trench between the first source/drain region and the second source/drain region and formed in the substrate, a cell gate insulating layer on sidewalls and a bottom surface of the trench, a cell gate electrode on the cell gate insulating layer, a work function control pattern on the cell gate electrode, including N-type impurities and a cell gate capping pattern on the work function control pattern. The work function control pattern includes a semiconductor material. The work function control pattern includes a first region and a second region between the first region and the cell gate electrode. A concentration of the N-type impurities in the first region is greater than a concentration of the N-type impurities in the second region.

Abstract: A cathode active material for a lithium secondary battery according to an embodiment of the present disclosure includes first lithium metal phosphate particles, each first lithium metal phosphate particle having a secondary particle shape formed by aggregation of primary particles and having an average particle diameter (D50) in a range from 5 ?m to 10 ?m, second lithium metal phosphate particles, each having a single particle and having an average particle diameter in a range from 1 ?m to 3 ?m, and third lithium metal phosphate particles, each having a single particle shape and having an average particle diameter less than 1 ?m.

Abstract: The present disclosure provides a novel biphenyl derivative compound or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound or pharmaceutically acceptable salt thereof according to the present disclosure is a compound that increases Nm23-H1/NDPK activity and can inhibit cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.

Abstract: A display device and a method of manufacturing the same are provided. The display device, comprises a first base substrate, a first barrier layer disposed on the first base substrate, a second base substrate disposed on the first barrier layer, at least one transistor disposed on the second base substrate, and an organic light emitting diode disposed on the at least one transistor, wherein the first barrier layer includes a silicon oxide, and has an adhesion force of 200 gf/inch or more to the second base substrate.

Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.

Abstract: A method is disclosed for measuring size of lesion from an image photographed by using a photographing device such as an endoscope. An image shown with lesion is shown on a screen, a lesion area is confirmed from the image shown on the screen, and the size of lesion area is calculated and displayed based on designated scale, whereby the size of lesion can be accurately provided, which is conducive to medical doctors in diagnosis and treatment.

Abstract: Disclosed is a method for preparing a mixed formulation of sustained release microspheres with various compositions by a continuous one-step process. The present method is characterized by preparing the mixed formulation of sustained release microspheres with different compositions by a continuous one-step process by continuously introducing the mixed fluids into a dryer from the two or more different fluids for preparation of sustained release microspheres containing a biodegradable polymer, a drug, an additive and a solvent with different types of contents or both of the components, by controlling the mixing ratios of the fluids according to the time, unlike a conventional method including spray-drying a mixture of microspheres containing a biodegradable polymer, a drug, an additive and a solvent with a single composition.

Abstract: The present invention relates to a sustained release formulation comprising protein as an active ingredient, and a preparation method thereof. According to the present invention, the sustained release formulation contains protein drugs that are encapsulated in biodegradable hydrophobic matrices as pharmaceutically active forms by forming complexes with sulfated polysaccharides. The sustained release formulation prepared by the present invention can be used to effectively treat a disease without frequent injections by keeping the protein concentration at a sufficiently high level for a long period when injected in vivo once.

Abstract: The present invention relates to controlled and sustained release pharmaceutical composition and processes for preparing the same. The present invention is to provide processes to prepare an injectable sustained release pharmaceutical composition comprising a step to prepare biodegradable porous microspheres having accessible ionic functional groups, a step to incorporate a biopharmaceutical into the microspheres through ionic interaction by suspending or equilibrating the microspheres in a solution containing the biopharmaceutical and a step to recover and freeze-dry the biopharmaceutical-incorporated microspheres.